Bio-Bridge Science Inc. Reports Encouraging Data in Pre-Clinical Trials of HIV Vaccine
February 01 2006 - 10:21AM
Business Wire
Bio-Bridge Science Inc. (OTCBB:BGES), a development-stage biotech
company, reported encouraging results for pharmacological and acute
toxicity studies on its HIV therapeutic Vaccine (HIV-PV
pseudovirus) on mice and monkeys. The vaccine, based on exclusive
technology co-developed by CEO Liang Qiao, an associate professor
at Loyola University Chicago's Stritch School of Medicine, targets
infection in mucosal tissues, the first type of tissue attacked by
HIV. The studies showed that the vaccine at low, medium and high
doses did not have any side effects on the central nervous system,
the cardiovascular system or the respiratory system of the animals.
No significant differences on blood cells and serum biochemical
parameters between pre and post treatment groups were observed
within 14 days after treatment. Dr. Liang Qiao, Chairman and CEO of
Bio-Bridge Science, said, "We are very pleased with the initial
results of the pre-clinical trials for our HIV Vaccine. We are
looking forward to receiving additional results in coming weeks
prior to commencing Phase 1 studies." About Bio-Bridge Science
Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is
expected to enter clinical trials in China in the very near future.
The vaccine, based on exclusive technology co-developed by CEO
Liang Qiao, an associate professor at Loyola University Chicago's
Stritch School of Medicine, targets infection in mucosal tissues,
the first type of tissue attacked by HIV. The Chinese government,
mindful of the rapid expansion of AIDS in China has, through the
"Green Mile Policy" acted to expedite the approval of domestically
produced HIV Vaccines and has dramatically increased its spending
on AIDS-related research. In accordance with this policy,
Bio-Bridge expects to bring its therapeutic HIV Vaccine to market
as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a
new $3 million state-of-the-art GMP research and manufacturing
facility in Beijing, which is expected to be completed in early
2006. Forward-Looking Statements This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information and
accompanying notes to financial statements.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024